Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors. Dr. Adair is a Co-Founder and Managing Director of Solas BioVentures, a venture capital fund that invests exclusively in the Life Sciences industry. Dr. Adair has extensive experience serving as a director on the boards of several pharmaceutical and medical device companies, including companies specializing in women’s health, in addition to 21 years as an OB/GYN Department Professor and Vice Chairman at the University of Tennessee College of Medicine in Chattanooga. Solas BioVentures intends to participate in the Mayfield Pharmaceuticals Series A financing.
Engineering biology is already transforming technology and science, and a consortium of researchers across many disciplines in the international Genome Project-write is calling for more discussion among scientists, policymakers and the general public to shepherd future development. In a policy forum article published in the October 18 issue of Science, the authors outline the technological advances needed to secure the transformative future of synthetic biology and express their concerns that the implementation of the relatively new discipline remains safe and responsible. Two researchers with the University of Tennessee Institute of Agriculture are co-authors on the piece titled "Technological challenges and milestones for writing genomes: synthetic genomics requires improved technologies."
CMS Administrator Seema Verma said Thursday that the healthcare system should encourage innovation, but "innovation doesn't mean anything" if people can't afford and access new drugs and therapies. Verma said that she's worried about the cost and access challenges posed by curative therapies during a discussion panel about healthcare costs at the TIME 100 Health Summit in New York. Curative therapies upend the traditional paradigm of managing disease by curing them instead, but the treatments are costly and unavailable to many patients who could benefit from them.
The Advanced Medical Technology Association (AdvaMed) today announced the launch of its Center for Digital Health, a new advocacy platform designed to advance digital health and the contributions of the medical technology industry to data-driven health care. The new Center builds on the success of the association’s Digital Health Sector, which was established in 2016 to serve the unique needs of companies in the burgeoning digital health space. AdvaMed’s Center for Digital Health will expand on that mission, addressing an ever-broadening set of issues that cut across industries—some of which are new to the health care arena—and a wide-ranging set of technologies and data uses that are increasingly pervasive across the medtech industry and in health care.